---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-024817"
form_type: "8-K"
ticker: "RANI"
cik: "0001856725"
company_name: "Rani Therapeutics Holdings, Inc."
filed_at: "2023-05-30T23:59:59+00:00"
generated_at: "2026-06-14T11:58:45.958136+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Rani Therapeutics annual meeting elects all director nominees; ratifies Ernst & Young as auditor

## Summary
- All 8 director nominees elected with substantial support; votes for each exceeded 226M, with withheld votes under 200K.
- Ratification of Ernst & Young as independent auditor passed: 230,587,049 for, 51 against, 2,301 abstain.
- Record date March 30, 2023: 25.4M Class A shares (1 vote each) and 24.1M Class B shares (10 votes each) outstanding.
- No other proposals were considered; all matters approved as recommended by the board.

## SEC filing metadata
- accession: 0000950170-23-024817
- form_type: 8-K
- ticker: RANI
- cik: 0001856725
- company_name: Rani Therapeutics Holdings, Inc.
- filed_at: 2023-05-30T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1856725/000095017023024817/0000950170-23-024817-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1856725/000095017023024817/rani-20230525.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-024817
- JSON: https://secwatch.observer/filing/0000950170-23-024817.json
- Plain text: https://secwatch.observer/filing/0000950170-23-024817.txt

## Key facts
- Shareholder Votes
  Rani Therapeutics Holdings, Inc. shareholders approved Ratification of the selection of Ernst & Young, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-05-25 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-05-25
  source text: The Company’s stockholders ratified the selection of Ernst & Young, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023, as follows: For: 230,587,049 Against: 51 Abstain: 2,301
  evidence_url: https://www.sec.gov/Archives/edgar/data/1856725/000095017023024817/0000950170-23-024817-index.htm
- Shareholder Votes
  Rani Therapeutics Holdings, Inc. shareholders approved Election of director nominees to hold office until the 2024 annual meeting of stockholders at the 2023-05-25 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-05-25
  source text: The Company’s stockholders elected the director nominees below, to hold office until the 2024 annual meeting of stockholders or until their successors are duly elected and qualified, as follows: For Withheld Broker Non-Votes Talat Imran 226,312,911 27,468 4,249,022 Mir Imran 226,125,068 215,311 4,249,022 Dennis Ausiello 226,152,615 187,764 4,249,022 Jean-Luc Butel 226,144,055 196,324 4,249,022 Laureen DeBuono 226,292,924 47,455 4,249,022 Andrew Farquharson 226,277,448 62,931 4,249,022 Malik Nanavaty 226,292,189 48,190 4,249,022 Lisa Rometty 226,314,568 25,811 4,249,022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1856725/000095017023024817/0000950170-23-024817-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.